ArticleCurrent drug targets2026
Identification of Natural Inhibitors against the
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a major public health challenge. In this study, the Mtb proteasome was targeted as a promising site for novel drug development.
methodsA total of 190,295 natural compounds from the ZINC database were screened using a systematic approach involving Lipinski's rule of five, SwissADME, pkCSM analysis, PyRx, and molecular dynamics simulation to identify potential drug candidates.
resultsFinally, five compounds, namely, ZINC14688701, ZINC299835179, ZINC14638395, ZINC299839873, and ZINC14638400, were identified based on physicochemical, pharmacokinetics, drug-likeness properties, and free energy of binding. Among these, ZINC14688701 showed the highest free energy of binding (-9.3 kcal/mol) with the selected target Mtb proteasome through the amino acid residues Thr1, Arg19, Ser20, Thr21, Val31, Lys33, Gly47, Thr48, Ala49, Leu99, Ser141, and Ala180. DISCUSSION: Finally, the complex 'Mtb proteasome-ZINC14688701' was studied using Molecular Dynamics simulation (MD simulation) for 50 ns, in which RMSD, RMSF, Rg, H-bonds, and SASA showed complex stability. Physicochemical evaluations revealed that the compounds are non-toxic with favorable drug-likeness. Exploring the antibacterial natural inhibitors offers a promising strategy for novel drug development against infectious diseases.
conclusionThese findings suggest a potential inhibitor of Mtb proteasome that could be used for TB treatment.
Indexed as
Identifiers
41508963What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.